These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36071264)

  • 1. Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting.
    Dong X; He X; Wu J
    Pharmacoeconomics; 2022 Dec; 40(12):1187-1205. PubMed ID: 36071264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
    Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
    JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
    Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
    Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
    Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
    Park SK; Hong SH; Kim H; Kim S; Lee EK
    Clin Ther; 2019 Jun; 41(6):1066-1079. PubMed ID: 31101372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
    Krittayaphong R; Permsuwan U
    Clin Drug Investig; 2021 Oct; 41(10):907-915. PubMed ID: 34533783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
    J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.
    Lou Y; Yu Y; Liu J; Huang J
    Front Public Health; 2022; 10():959139. PubMed ID: 36062091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
    Krittayaphong R; Permsuwan U
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Yan BW; Spahillari A; Pandya A
    Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
    Liu XQ; He LS; Huang JQ; Xiong LJ; Xia C; Lao HY
    Heart Fail Rev; 2021 Sep; 26(5):1119-1130. PubMed ID: 32405811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril-valsartan
    Hu T; Liu Y; Lou Y
    Front Pharmacol; 2023; 14():925375. PubMed ID: 36937882
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
    JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    McMurray JJV; Trueman D; Hancock E; Cowie MR; Briggs A; Taylor M; Mumby-Croft J; Woodcock F; Lacey M; Haroun R; Deschaseaux C
    Heart; 2018 Jun; 104(12):1006-1013. PubMed ID: 29269379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis.
    Perera K; Ademi Z; Liew D; Zomer E
    Eur J Prev Cardiol; 2021 Aug; 28(9):966-972. PubMed ID: 34402869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
    Zacà V
    J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):597-605. PubMed ID: 30160656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.